The market for ApiFix surpasses $1.15 billion globally, with ApiFix receiving the CE mark in 2012. Surgeons have used ApiFix in more than 100 operations. B. Braun and Trendlines partnered last year, with the two companies working together on new investment opportunities as well as devising new products. B. Braun took on a lead position in ApiFix’s B round financing, with the company’s Aesculap division investing $2.8 million in the $5 million round. The financing round is projected to close by the end of this year.
You are here: / / / B. Braun, Trendlines partner on ApiFix investment — 4 takeaways